Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.

An international team led by researchers at Lund University in Sweden has identified the molecular tools needed to reprogram ordinary cells into specialized immune cells. The discovery, published in ...

A groundbreaking human trial of ER-100, a cellular reprogramming therapy, has begun, testing whether damaged eye cells can be rejuvenated and potentially opening a new chapter in the science of aging.

Retinal degeneration leads to irreversible vision loss and significantly impacts quality of life. Approximately 19.83 million Americans over the age of 40 are affected by age-related macular ...

For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research lays a foundation for the possibility that aggressive prostate cancer can ...

Cancer cells rapidly adapt to treatments, developing resistance that makes chemotherapy less effective. Researchers used an existing anti-inflammatory drug to disrupt cancer cells’ ability to adapt by ...

“How old would you like to be when you die?” That’s the question my primary care physician asked during my routine physical. It’s a complex question, one without a right answer. As long as possible, ...

In a breakthrough for longevity science, a reverse-aging treatment has been injected into a human. The technique is a sought-after solution for improving longevity by reprogramming cells. Competitors ...